• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Chronic Inflammatory Demyelinating Polyneuropathy

Chronic Inflammatory Demyelinating Polyneuropathy - 26 Studies Found

Completed : Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients.
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2012-06-19
:
  • Drug: Fingolimod
  • Drug: Placebo Comparator

Completed : Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2004-12-15
: Drug: Interferon Beta-1a
Completed : Effect of Resistance and Aerobic Exercise in CIDP or MMN
:
  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Multifocal Mo
    : 2014-02-17
    :
    • Other: Resistance training

Withdrawn : Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy
: Chronic Inflammatory Demyelinating Polyneuropathy
: 2015-08-30
: Drug: H.P. Acthar® Gel Other Names:
  • Acthar® Gel
  • repo

Not yet recruiting : Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2016-08-29
:
  • Procedure: Muscle Magnetic Resonance Imaging (RMI) evaluation

Completed : MRI in Diagnosing and Monitoring CIDP
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2013-12-06
Completed : Efficacy and Safety Study of I10E in Treatment of Patients With CIDP
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2014-11-13
: Drug: I10E Patients who meet all eligibility criteria will
Completed : Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2014-12-11
: Drug: I10E Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 4
Completed : Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2016-11-02
: Biological: HYQVIA Other Names:
  • IGI 10% with rHuPH20
  • Immune Gl

Completed : Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP
: Chronic Inflammatory Demyelinating Polyradiculoneuropathy
: 2015-09-11
:
  • Biological: HYQVIA Dosing regi

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.